-

$undefined

N/A

(N/A)

Gyre Therapeutics Inc NasdaqCM:GYRE Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Location: 12770 High Bluff Drive, San Diego, CA, 92130, United States | Website: https://www.gyretx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

841.3M

Cash

29.89M

Avg Qtr Burn

-1.664M

Short % of Float

12.72%

Insider Ownership

85.75%

Institutional Own.

2.81%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Avatrombopag Details
Thrombocytopenia , Chronic liver disease

Approved

Quarterly sales

F351 (Hydronidone) Details
Chronic hepatitis B, Liver fibrosis

Phase 3

Data readout

F573 Details
Acute-on-Chronic liver failure

Phase 2

Data readout

F351 (Hydronidone) Details
Metabolic dysfunction-associated steatohepatitis (“MASH”)-related fibrosis

Phase 2

Initiation

F351 (Hydronidone) Details
Non-alcoholic steatohepatitis , Liver fibrosis

Phase 2a

Initiation

F230 Details
Pulmonary arterial hypertension

Phase 1

Initiation